BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study

References

• Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244–253. doi:10.1097/00124509-200112000-0000311731725
   PubMed Web of Science ®Google Scholar
• Zheng W, Li XH, Zhu XM, et al. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: a meta-analysis of randomized controlled trials. J Affect Disord. 2019;250:123–131. doi:10.1016/j.jad.2019.02.04430852364
   PubMed Web of Science ®Google Scholar
• Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT. 2012;28(2):128–132. doi:10.1097/YCT.0b013e31824d1d0222622291
   PubMed Web of Science ®Google Scholar
• Yalcin S, Aydogan H, Selek S, et al. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J Anesth. 2012;26(4):562–567. doi:10.1007/s00540-012-1378-622623080
   PubMed Web of Science ®Google Scholar
• Chen J, Peng LH, Luo J, et al. Effects of low-dose ketamine combined with propofol on phosphorylation of AMPA receptor GluR1 subunit and GABAA receptor in hippocampus of stressed rats receiving electroconvulsive shock. J ECT. 2015;31(1):50–56. doi:10.1097/YCT.000000000000014824831997
   PubMed Web of Science ®Google Scholar
• Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry. 2003;54(7):703–709. doi:10.1016/S0006-3223(03)00073-814512210
   PubMed Web of Science ®Google Scholar
• Ryan KM, Dunne R, McLoughlin DM. BDNF plasma levels and genotype in depression and the response to electroconvulsive therapy. Brain Stimul. 2018;11(5):1123–1131. doi:10.1016/j.brs.2018.05.01129802070
   PubMed Web of Science ®Google Scholar
• Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014;19(7):791–800. doi:10.1038/mp.2013.10523958957
   PubMed Web of Science ®Google Scholar
• Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord. 2015;174:432–440. doi:10.1016/j.jad.2014.11.04425553404
   PubMed Web of Science ®Google Scholar
• Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11(8):1169–1180. doi:10.1017/S146114570800930918752720
   PubMed Web of Science ®Google Scholar
• Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 2007;12(12):1079–1088. doi:10.1038/sj.mp.400207517700574
   PubMed Web of Science ®Google Scholar
• Kurita M, Nishino S, Kato M, Numata Y, Sato T, Buch SJ. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS One. 2012;7(6):e39212. doi:10.1371/journal.pone.003921222761741
   PubMed Web of Science ®Google Scholar
• Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231(18):3663–3676. doi:10.1007/s00213-014-3664-525038867
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46(7):1459–1472. doi:10.1017/S003329171600006426867988
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704. doi:10.1017/S003329171400160325010396
   PubMed Web of Science ®Google Scholar
• Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18(1):pyu033.25539510
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhou YL, Liu WJ, et al. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. J Psychopharmacol. 2019;33(4):494–501. doi:10.1177/026988111982781130789302
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. doi:10.1136/jnnp.23.1.5614399272
   PubMed Web of Science ®Google Scholar
• Zhang M, Rosenheck R, Lin X, et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J Affect Disord. 2018;227:372–378. doi:10.1016/j.jad.2017.11.03429149755
   PubMed Web of Science ®Google Scholar
• Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol. 1984;39(2):187–193. doi:10.1093/geronj/39.2.1876699374
   PubMedGoogle Scholar
• Zhan Y, Zhang B, Zhou Y, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019;251:205–212. doi:10.1016/j.jad.2019.03.07130927581
   PubMed Web of Science ®Google Scholar
• van Zutphen EM, Rhebergen D, van Exel E, et al. Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome. Transl Psychiatry. 2019;9(1):155. doi:10.1038/s41398-019-0491-931127089
   PubMed Web of Science ®Google Scholar
• Naegelin Y, Dingsdale H, Säuberli K, Schädelin S, Kappos L, Barde Y-A. Measuring and validating the levels of brain-derived neurotrophic factor in human serum. Eneuro. 2018;5(2):1–9.
   Web of Science ®Google Scholar
• Kishi T, Yoshimura R, Ikuta T, Iwata N. Brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses. Front Psychiatry. 2017;8:308. doi:10.3389/fpsyt.2017.0030829387021
   PubMed Web of Science ®Google Scholar
• Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527–532. doi:10.1016/j.biopsych.2008.05.00518571629
   PubMed Web of Science ®Google Scholar
• Hellweg R, Ziegenhorn A, Heuser I, Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry. 2008;41(2):66–71. doi:10.1055/s-2007-100459418311687
   PubMed Web of Science ®Google Scholar
• Ng QX, Ramamoorthy K, Loke W, et al. Clinical role of aspirin in mood disorders: a systematic review. Brain Sci. 2019;9(11):296. doi:10.3390/brainsci9110296
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen M-C, Lee W-K, Chen -C-C, Huang C-H, Lane H-Y. Electroconvulsive therapy improves clinical manifestation with plasma bdnf levels unchanged in treatment-resistant depression patients. Neuropsychobiology. 2013;68(2):110–115. doi:10.1159/00035201323881232
   PubMed Web of Science ®Google Scholar
• Fernandes B, Gama CS, Massuda R, et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci Lett. 2009;453(3):195–198. doi:10.1016/j.neulet.2009.02.03219429034
   PubMed Web of Science ®Google Scholar
• Gedge L, Beaudoin A, Lazowski L, Du Toit R, Jokic R, Milev R. Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. Front Psychiatry. 2012;3:12. doi:10.3389/fpsyt.2012.0001222375129
   PubMedGoogle Scholar
• Gronli O, Stensland GO, Wynn R, Olstad R. Neurotrophic factors in serum following ECT: a pilot study. World J Biol Psychiatry. 2009;10(4):295–301. doi:10.3109/1562297070158632319921971
   PubMed Web of Science ®Google Scholar
• Sorri A, Jarventausta K, Kampman O, et al. Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder. Brain Behav. 2018;8(11):e01101. doi:10.1002/brb3.2018.8.issue-1130273985
   PubMed Web of Science ®Google Scholar
• Rapinesi C, Kotzalidis GD, Curto M, et al. Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels. Psychiatry Res. 2015;227(2–3):171–178. doi:10.1016/j.psychres.2015.04.00925910420
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70(12):1662–1666. doi:10.4088/JCP.08m0465919744406
   PubMed Web of Science ®Google Scholar
• Rocha RB, Dondossola ER, AnJ G, et al. Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: a meta-analysis study. J Psychiatr Res. 2016;83:47–53. doi:10.1016/j.jpsychires.2016.08.00427552533
   PubMed Web of Science ®Google Scholar
• Stelzhammer V, Guest PC, Rothermundt M, et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur Neuropsychopharmacol. 2013;23(10):1199–1207. doi:10.1016/j.euroneuro.2012.10.01223183131
   PubMed Web of Science ®Google Scholar
• Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacol. 1998;37(12):1553–1561. doi:10.1016/S0028-3908(98)00141-5
   PubMed Web of Science ®Google Scholar
• Okamoto T, Yoshimura R, Ikenouchi-Sugita A, et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1185–1190. doi:10.1016/j.pnpbp.2008.02.00918403081
   PubMed Web of Science ®Google Scholar
• Bilgen AE, Bozkurt Zincir S, Zincir S, et al. Effects of electroconvulsive therapy on serum levels of brain-derived neurotrophic factor and nerve growth factor in treatment resistant major depression. Brain Res Bull. 2014;104:82–87. doi:10.1016/j.brainresbull.2014.04.00524747833
   PubMed Web of Science ®Google Scholar
• Marano CM, Phatak P, Vemulapalli UR, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry. 2007;68(4):512–517. doi:10.4088/JCP.v68n040417474805
   PubMed Web of Science ®Google Scholar
• Piccinni A, Del Debbio A, Medda P, et al. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol. 2009;19(5):349–355. doi:10.1016/j.euroneuro.2009.01.00219223156
   PubMed Web of Science ®Google Scholar
• Bumb JM, Aksay SS, Janke C, et al. Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2015;265(3):227–232. doi:10.1007/s00406-014-0543-325231834
   PubMed Web of Science ®Google Scholar
• Hu Y, Yu X, Yang F, et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT. 2010;26(2):121–125. doi:10.1097/YCT.0b013e3181c18bbf19935088
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhou YL, Liu WJ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61–68. doi:10.1016/j.jpsychires.2018.09.01330278319
   PubMed Web of Science ®Google Scholar
• Kurdi M, Theerth K, Deva R. Ketamine:current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283–290. doi:10.4103/0259-1162.14311025886322
   PubMedGoogle Scholar
• Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020;263:568–575. doi:10.1016/j.jad.2019.11.02831791675
   PubMed Web of Science ®Google Scholar
• Ketalar (Ketamine Hydrochloride) Injection. U.S. Food & Drug Administration; 2019.
   Google Scholar
• Martinez V, Derivaux B, Beloeil H. Ketamine for pain management in France, an observational survey. Anaesth Crit Care Pain Med. 2015;34(6):357–361. doi:10.1016/j.accpm.2015.04.00526541218
   PubMed Web of Science ®Google Scholar
• Han E, Kwon NJ, Feng LY, Li JH, Chung H. Illegal use patterns, side effects, and analytical methods of ketamine. Forensic Sci Int. 2016;268:25–34. doi:10.1016/j.forsciint.2016.09.00127685472
   PubMed Web of Science ®Google Scholar